213f702a-56fd-4ab0-940c-a71e4e01b6f8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- OXIDATIVE_PHOSPHORYLATION+0.540
- INTERFERON_GAMMA_RESPONSE+0.400
- E2F_TARGETS+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- DNA_REPAIR+0.310
- G2M_CHECKPOINT+0.290
- FATTY_ACID_METABOLISM+0.260
- MYC_TARGETS_V2+0.260
- GLYCOLYSIS+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- UV_RESPONSE_DN-0.450
- WNT_BETA_CATENIN_SIGNALING-0.400
- TGF_BETA_SIGNALING-0.380
- ANGIOGENESIS-0.370
- HEDGEHOG_SIGNALING-0.350
- NOTCH_SIGNALING-0.340
- MYOGENESIS-0.330
- ANDROGEN_RESPONSE-0.260
- CHOLESTEROL_HOMEOSTASIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-A6UM-01A-12R-A34R-07 | — | — | 0.853 |
| 2 | TCGA-KU-A6H7-01A-11R-A31N-07 | — | — | 0.843 |
| 3 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.833 |
| 4 | TCGA-CV-6433-01A-11R-1686-07 | — | — | 0.829 |
| 5 | SRR8518323 | — | E | 0.827 |
| 6 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.824 |
| 7 | 7c8246a6-3f2c-42e1-b09f-959cfbf7fd5a | — | — | 0.822 |
| 8 | SRR8518289 | — | E | 0.814 |
| 9 | TCGA-T2-A6WX-01A-12R-A34R-07 | — | — | 0.810 |
| 10 | TCGA-AR-A0TV-01A-21R-A084-07 | — | B | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |